NYSE: LCILannett Co Inc Stock
$0.67-0.01 (-1.47%)
Updated Feb 3, 2023
LCI Price
$0.67
Fair Value Price
N/A
Market Cap
$28.98M
52 Week Low
$0.39
52 Week High
$1.01
P/E
-0.14x
P/B
-0.09x
P/S
0.07x
PEG
N/A
Dividend Yield
N/A
Revenue
$308.52M
Earnings
-$192.52M
Gross Margin
12.3%
Operating Margin
-43.37%
Profit Margin
-62.4%
Debt to Equity
-2.4
Operating Cash Flow
-$51M
Beta
0.76
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
LCI Overview
Lannett Co, Inc. manufactures generic versions of brand pharmaceutical products in the U.S. Its primary products include Levothyroxine Sodium tablets, Fluphenazine tablets, Posaconazole DR tablets, and Verapamil SR tablets. Lannett was incorporated in 1942 and is headquartered in Trevose, PA.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how LCI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LCI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
LCI is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
LCI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more LCI due diligence checks available for Premium users.
Be the first to know about important LCI news, forecast changes, insider trades & much more!
LCI News
Valuation
LCI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.14x
Industry
18.24x
Market
15.09x
LCI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.09x
Industry
1.9x
LCI's financial health
Profit margin
Revenue
$80.9M
Net Income
-$36.3M
Profit Margin
-44.9%
LCI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
LCI's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$438.4M
Liabilities
$750.6M
Debt to equity
-2.4
LCI's short-term assets ($250.53M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LCI's long-term liabilities ($638.42M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LCI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LCI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$19.2M
Investing
-$2.9M
Financing
$29.0k
LCI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LCI vs Pharmaceutical Stocks
Lannett Co Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.